Joel E Gallant

发表

False positive viral load results: recent problems and solutions.

Joel E Gallant, J. Gallant, 2005, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Tara L. Kieffer, Joel E Gallant, Charles Flexner, 2005, JAMA.

Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition.

Joel E Gallant, Adaora A Adimora, Michael Horberg, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

Joel E Gallant, Calvin Cohen, Edwin DeJesus, 2003, AIDS.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Michael S Saag, Huldrych F Günthard, 2016, JAMA.

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Joel E Gallant, David D Celentano, Stephen J Gange, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

Joel E Gallant, J. Gallant, L. Wilson, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance

Joel E Gallant, R. Haubrich, D. Richman, 2002, Antiviral therapy.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Amalio Telenti, Michael S Saag, 2014, JAMA.

The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.

Joel E Gallant, J. Gallant, 2006, The AIDS reader.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Joel E Gallant, Edwin DeJesus, B. Gazzard, 2006, The New England journal of medicine.